Trial Profile

Phase I/II Study of Allogeneic Hematopoietic Stem Cell Transplantation From an HLA-partially Matched Family Donor After TCR Alfa Beta Negative Selection in Pediatric Patients Affected by Hematological Disorders

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 21 Jan 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Antithymocyte globulin (Primary) ; Rituximab
Indications Acute myeloid leukaemia; Haematological disorders; Myelodysplastic syndromes; Precursor cell lymphoblastic leukaemia-lymphoma
Focus Therapeutic Use

14 Dec 2021 Results (N=23) assessing safety and effectiveness of Alphabeta T and B-Cell Depleted HLA-Haploidentical Hematopoietic Stem Cell Transplantation in Children with Myelodysplastic Syndromes, presented at the 63rd American Society of Hematology Annual Meeting and Exposition
08 Dec 2020 Results (n=80) presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology
21 Jan 2019 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com